VASTox will use grant funds to further stem cell research

By Lisa Kerner

Charlotte, N.C., Sept. 20 - VASTox plc will begin a new proprietary drug discovery program involving stem cells supported by grant funding from the U.K. Department of Trade and Industry under its Technology Program.

The grant will fund an 18-month £910,000 collaborative research program with leading academics to screen small molecules in zebra fish and fruit flies to identify compounds that affect stem cell division, proliferation and behavior. VASTox will match the £370,000 it is slated to receive from the grant.

Successful hits can be developed into regenerative therapies for the treatment of Crohn's disease, Parkinson's disease and cancer, the company said.

VASTox is a chemical genomics technology company located in Oxford, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.